Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY

November 26, 2024 7:05 AM EST

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight

MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study

In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2.2 Percentage Points at 52 Weeks

MariTide Delivered Substantial Improvements Across... More

AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM

November 26, 2024 7:00 AM EST

THOUSAND OAKS, Calif., Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to discuss data from the 52-week, Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and progress on its development program. Participating in the call... More